EUCTR2006-001247-64-SE进行中（未招募）不适用
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - NA
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Advanced (unresectable or metastatic) biopsy-proven pancreatic NET
- •Confirmed low-grade or intermediate-grade neuroendocrine carcinoma
- •Objective disease progression by RECIST criteria while receiving cytotoxic chemotherapy or at any time after receiving an adequate course of cytotoxic chemotherapy (i.e., at least 3 consecutive cycles or months of treatment with the same cytotoxic drug or regimen)
- •Presence of at least one measurable disease using RECIST criteria at screening (CT or MRI)
- •Adequate bone marrow, liver and kidney function Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with poorly differentiated neuroendocrine carcinoma
- •Hepatic artery embolization within the last 6 months
- •Prior therapy with everolimus or other rapamycins (sirolimus, temsirolimus)
- •Other concurrent malignancy
- •Other serious intercurrent infections or nonmalignant uncontrolled medical illnesses Other protocol-defined exclusion criteria may apply
研究者
相似试验
尚未招募
2 期
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapyadvanced islet cell carcinomaadvanced pancreatic neuroendocrine tumor1002911210014713NL-OMON29869ovartis8
进行中（未招募）
不适用
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - NAPancreatic neuroendocrine tumors (NET) comprise only 1-2% of all pancreatic tumors. The annual incidence is approx. 3.5 to 4 per million population. The hormones secreted by pancreatic NET depend upon the cell of origin and are physiologically involved in a network of autocrine, paracrine, endocrine and neurotransmitter communication. While hormone secretion is not observed in all cases, the nonfunctioning” pancreatic NET tend to be more aggressive and present with symptoms of tumor bulk.EUCTR2006-001247-64-NLovartis Pharma Services AG144
进行中（未招募）
1 期
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy. - NAPancreatic neuroendocrine tumors (NET) comprise only 1-2% of all pancreatic tumors. The annual incidence is approx. 3.5 to 4 per million population. The hormones secreted by pancreatic NET depend upon the cell of origin and are physiologically involved in a network of autocrine, paracrine, endocrine and neurotransmitter communication. While hormone secretion is not observed in all cases, the nonfunctioning” pancreatic NET tend to be more aggressive and present with symptoms of tumor bulk.EUCTR2006-001247-64-BEovartis Pharma Services AG144
进行中（未招募）
不适用
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapyEUCTR2006-001247-64-ESovartis Farmaceutica, S.A144
进行中（未招募）
不适用
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - NAPancreatic neuroendocrine tumors (NET) comprise only 1-2% of all pancreatic tumors. The annual incidence is approx. 3.5 to 4 per million population. The hormones secreted by pancreatic NET depend upon the cell of origin and are physiologically involved in a network of autocrine, paracrine, endocrine and neurotransmitter communication. While hormone secretion is not observed in all cases, the nonfunctioning” pancreatic NET tend to be more aggressive and present with symptoms of tumor bulk.EUCTR2006-001247-64-DEovartis Pharma Services AG144